查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1767752

全球感染疾病体外诊断市场按产品类型、最终用户、地区、产业分析、规模、份额、成长、趋势和预测（2025-2032 年）

Infectious Disease In-vitro Diagnostics Market by Product Type, End-Users, and Geography: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 188 Pages | 商品交期: 2-5个工作天内

价格
简介目录

主要发现

  • 感染疾病IVD市场规模（2025年）：466亿美元
  • 预计市场价值（2032年）：641亿美元
  • 全球市场成长率：4.7%（2025年至2032年的复合年增长率）

感染疾病体外诊断市场 - 报告范围

感染疾病体外诊断在快速准确地检测导致爱滋病毒、肝炎、流感、结核病和 SARS-CoV-2 等新兴病毒威胁的感染疾病方面发挥着至关重要的作用。这些诊断技术包括分子检测、免疫测定和就地检验技术，有助于早期诊断、指导治疗决策并促进感染控制工作。感染疾病体外诊断市场面向医院、临床实验室、诊断中心和照护现场，提供各种检测套组、试剂、仪器和软体解决方案。市场成长的驱动力包括感染疾病的流行、对快速准确检测日益增长的需求，以及诊断平台的技术进步，从而提高了灵敏度、特异性和周转时间。

市场成长动力

全球感染疾病诊断 (IVD) 市场受到多种因素驱动，例如全球感染疾病病率的上升、人们对早期发现和疾病控制意识的不断增强。抗生素抗药性感染疾病的增加、疫情爆发时对精准诊断的需求以及政府对感染疾病监测和筛检的强有力支持，进一步推动了市场的成长。分子诊断技术的进步，例如次世代定序和多重 PCR，使得同时检测多种病原体成为可能，从而改善了临床决策和患者预后。此外，在分散的医疗机构中，就地检验在传染病筛检中的应用日益广泛，这为诊断提供了便利和快速的途径，尤其是在资源匮乏的地区，从而显着促进了市场扩张。

市场限制

儘管感染疾病体外诊断市场预计将迎来可观的成长，但它仍面临着许多挑战，包括严格的法规结构、复杂的核准流程以及某些地区报销额度有限。各国监管要求的差异化不仅阻碍了其全球市场渗透，也增加了製造商的开发时间和成本。此外，先进的分子诊断系统和检测方法价格昂贵，这可能会限制其普及，尤其是在预算限制影响医疗保健成本的中低收入国家。此外，对于检测准确性、假阳性或假阴性结果以及分散环境下的品管的担忧，也对市场参与企业构成持续挑战，因为他们需要努力保持诊断的可靠性和临床信心。

市场机会

感染疾病体外诊断市场在技术创新、全球卫生重点和不断发展的诊断需求的推动下，提供了巨大的成长机会。云端基础的数据管理和人工智慧主导的诊断演算法等数位健康工具的集成，提高了诊断准确性，并实现了远端分析，从而支援疾病监测和疫情追踪。此外，对新型生物标记、快速诊断检测和综合检测试剂盒研发的持续投入，将拓宽市场范围，并满足临床上尚未满足的需求。个人化医疗的转变、公私合营的加强以及对新兴感染疾病防范的重视，为市场公司开发创新解决方案并增强其在瞬息万变的感染疾病诊断领域的市场影响创造了途径。

本报告研究了全球感染疾病体外诊断市场，并对市场动态进行了详细分析，包括成长动力、趋势、机会和挑战。

目录

第一章执行摘要

第二章 市场概述

  • 市场范围和定义
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
    • 任务
    • 主要趋势
  • 宏观经济因素
    • 全球产业展望
    • 全球GDP成长前景
  • COVID-19影响分析
  • 预测因子－相关性和影响力

第三章 增值考虑

  • 监管格局
  • 产品采用分析
  • 价值链分析
  • 重大交易及合併
  • PESTLE分析
  • 波特五力分析

第四章 全球感染疾病体外诊断市场展望

  • 主要亮点
    • 市场规模及年成长
    • 绝对的商机
  • 市场规模分析及预测
    • 市场规模表现分析（2019-2024）
    • 当前市场规模分析与预测（2025-2032）
  • 全球感染疾病体外诊断市场展望（依产品类型）
    • 简介/主要发现
    • 按产品类型分類的历史市场规模分析（2019-2024）
    • 按产品类型分類的当前市场规模分析和预测（2025-2032）
      • 装置
      • 试剂
      • 软体、服务
    • 按产品类型进行市场吸引力分析
  • 全球感染疾病体外诊断市场展望：技术
    • 简介/主要发现
    • 依技术分類的市场规模绩效分析（2019-2024）
    • 目前市场规模分析及技术预测（2025-2032）
      • 免疫测量
      • 分子诊断
      • 微生物学
      • 其他的
    • 市场吸引力分析：技术
  • 全球感染疾病体外诊断市场展望：应用
    • 简介/主要发现
    • 历史市场规模分析：按应用（2019-2024）
    • 目前市场规模分析及应用预测（2025-2032）
      • MRSA
      • 困难梭状芽孢桿菌
      • 呼吸道病毒
      • 结核病、抗药性结核病
      • 淋病
      • HPV
      • HIV
      • C型肝炎
      • B型肝炎
      • COVID-19
      • 其他的
    • 市场吸引力分析：应用
  • 全球感染疾病体外诊断市场展望：最终用户
    • 简介/主要发现
    • 按最终用户分類的市场规模绩效分析（2019-2024 年）
    • 目前市场规模分析及最终用户预测（2025-2032）
      • 照护现场
      • 中央考场
      • 其他的
    • 市场吸引力分析：最终用户

5. 全球感染疾病体外诊断市场（按地区）展望

  • 主要亮点
  • 市场规模绩效分析：按地区（2019-2024）
  • 目前市场规模分析及各地区预测（2025-2032）
    • 北美洲
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：地区

6. 北美感染疾病体外诊断市场展望

7. 欧洲感染疾病体外诊断市场展望

第八章东亚感染疾病体外诊断市场展望

9.南亚及大洋洲感染疾病体外诊断市场展望

10. 拉丁美洲感染疾病体外诊断市场展望

第11章中东和非洲感染疾病体外诊断市场展望

第十二章竞争格局

  • 市场占有率分析（2025年）
  • 市场结构
    • 竞争强度图：按市场
    • 竞争仪錶板
  • 公司简介（详情－概述、财务状况、策略、最新发展）
    • QIAGEN
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche, Ltd.
    • Hologic, Inc. (Gen Probe)
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • OraSure Technologies, Inc.
    • 其他的

第十三章 附录

简介目录
Product Code: PMRREP33205

Persistence Market Research has recently released a comprehensive report on the worldwide market for infectious disease in-vitro diagnostics (IVD). The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global infectious disease IVD market from 2025 to 2032.

Key Insights:

  • Infectious Disease IVD Market Size (2025E): USD 46.6 Billion
  • Projected Market Value (2032F): USD 64.1 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 4.7%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

Infectious disease in-vitro diagnostics play a crucial role in the rapid and accurate detection of pathogens responsible for infections such as HIV, hepatitis, influenza, tuberculosis, and emerging viral threats like SARS-CoV-2. These diagnostics encompass molecular assays, immunoassays, and point-of-care testing technologies, enabling early diagnosis, guiding treatment decisions, and facilitating infection control efforts. The infectious disease IVD market caters to hospitals, clinical laboratories, diagnostic centers, and point-of-care settings, offering a diverse array of test kits, reagents, instruments, and software solutions. Market growth is driven by the rising prevalence of infectious diseases, increased demand for rapid and accurate testing, and technological advancements in diagnostic platforms, improving sensitivity, specificity, and turnaround times.

Market Growth Drivers:

The global infectious disease IVD market is propelled by several key factors, including the growing incidence of infectious diseases worldwide and heightened awareness of early detection and disease management. The increasing burden of antibiotic-resistant infections, the need for precise diagnostics in outbreak scenarios, and robust government initiatives supporting infectious disease surveillance and screening further accelerate market growth. Technological progress in molecular diagnostics, such as next-generation sequencing and multiplex PCR, enables simultaneous detection of multiple pathogens, enhancing clinical decision-making and patient outcomes. Moreover, the expanding use of point-of-care tests for infectious disease screening in decentralized healthcare settings contributes significantly to market expansion, offering convenience and faster diagnosis, especially in resource-limited regions.

Market Restraints:

Despite promising growth prospects, the infectious disease IVD market faces challenges related to stringent regulatory frameworks, complex approval processes, and reimbursement limitations in certain regions. Variations in regulatory requirements across countries create barriers for global market penetration and increase development timelines and costs for manufacturers. Additionally, the high cost of advanced molecular diagnostic systems and tests can restrict adoption, particularly in low- and middle-income countries where budget constraints affect healthcare spending. Moreover, concerns around test accuracy, false-positive or false-negative results, and quality control in decentralized settings pose ongoing challenges for market players striving to maintain diagnostic reliability and clinical trust.

Market Opportunities:

The infectious disease IVD market presents significant growth opportunities driven by technological innovations, global health priorities, and evolving diagnostic needs. The integration of digital health tools, such as cloud-based data management and artificial intelligence-driven diagnostic algorithms, improves diagnostic accuracy, enables remote analysis, and supports disease surveillance and outbreak tracking. Furthermore, rising investment in research and development for novel biomarkers, rapid diagnostic tests, and syndromic testing panels expands the market scope and addresses unmet clinical needs. The shift toward personalized medicine, increased public-private collaborations, and growing emphasis on preparedness for emerging infectious diseases create avenues for market players to develop innovative solutions and strengthen market presence in the dynamic infectious disease diagnostics landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the infectious disease IVD market globally?
  • Which test types and applications are driving the adoption of infectious disease diagnostics across various healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the infectious disease IVD market?
  • Who are the key players contributing to the infectious disease IVD market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global infectious disease IVD market?

Competitive Intelligence and Business Strategy:

These companies invest in R&D to develop high-sensitivity molecular assays, multiplexed platforms, and rapid point-of-care diagnostics, addressing diverse infectious disease testing needs. Partnerships with healthcare providers, governments, and international health organizations facilitate access to markets, especially during public health emergencies. Moreover, emphasis on automation, integration of digital solutions, and adherence to regulatory standards enables market leaders to deliver reliable, scalable, and cost-effective diagnostic solutions. Continuous efforts in clinical research, assay validation, and global distribution networks further consolidate the competitive landscape in the rapidly evolving infectious disease IVD market.

Key Companies Profiled:

  • QIAGEN
  • Becton, Dickinson and Company
  • bioMerieux SA
  • F. Hoffmann-La Roche, Ltd.
  • Hologic, Inc. (Gen Probe)
  • Abbott
  • Quidel Corporation
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • OraSure Technologies, Inc.

Infectious Disease IVD Market Research Segmentation:

The infectious disease IVD market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various pathogens and patient populations.

By Product Type

  • Instruments
  • Reagents
  • Software and Services

By Technology

  • Immunoassay
  • Molecular Diagnostics
  • Microbiology
  • Others

By Application

  • MRSA
  • Clostridium Difficile
  • Respiratory Virus
  • TB and Drug-resistant TB
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others

By End User

  • Point-of-care
  • Central Laboratories
  • Others

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Infectious Disease In-vitro Diagnostics Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Infectious Disease In-vitro Diagnostics Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Infectious Disease In-vitro Diagnostics Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
      • 4.3.3.1. Instruments
      • 4.3.3.2. Reagents
      • 4.3.3.3. Software and Services
    • 4.3.4. Market Attractiveness Analysis: Product Type
  • 4.4. Global Infectious Disease In-vitro Diagnostics Market Outlook: Technology
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
      • 4.4.3.1. Immunoassay
      • 4.4.3.2. Molecular Diagnostics
      • 4.4.3.3. Microbiology
      • 4.4.3.4. Others
    • 4.4.4. Market Attractiveness Analysis: Technology
  • 4.5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Application
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.5.3.1. MRSA
      • 4.5.3.2. Clostridium Difficile
      • 4.5.3.3. Respiratory Virus
      • 4.5.3.4. TB and Drug-resistant TB
      • 4.5.3.5. Gonorrhea
      • 4.5.3.6. HPV
      • 4.5.3.7. HIV
      • 4.5.3.8. Hepatitis C
      • 4.5.3.9. Hepatitis B
      • 4.5.3.10. COVID-19
      • 4.5.3.11. Others
    • 4.5.4. Market Attractiveness Analysis: Application
  • 4.6. Global Infectious Disease In-vitro Diagnostics Market Outlook: End User
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.6.3.1. Point-of-care
      • 4.6.3.2. Central Laboratories
      • 4.6.3.3. Others
    • 4.6.4. Market Attractiveness Analysis: End User

5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Infectious Disease In-vitro Diagnostics Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product Type
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 6.4.1. Instruments
    • 6.4.2. Reagents
    • 6.4.3. Software and Services
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 6.5.1. Immunoassay
    • 6.5.2. Molecular Diagnostics
    • 6.5.3. Microbiology
    • 6.5.4. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.6.1. MRSA
    • 6.6.2. Clostridium Difficile
    • 6.6.3. Respiratory Virus
    • 6.6.4. TB and Drug-resistant TB
    • 6.6.5. Gonorrhea
    • 6.6.6. HPV
    • 6.6.7. HIV
    • 6.6.8. Hepatitis C
    • 6.6.9. Hepatitis B
    • 6.6.10. COVID-19
    • 6.6.11. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.7.1. Point-of-care
    • 6.7.2. Central Laboratories
    • 6.7.3. Others
  • 6.8. Market Attractiveness Analysis

7. Europe Infectious Disease In-vitro Diagnostics Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product Type
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 7.4.1. Instruments
    • 7.4.2. Reagents
    • 7.4.3. Software and Services
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 7.5.1. Immunoassay
    • 7.5.2. Molecular Diagnostics
    • 7.5.3. Microbiology
    • 7.5.4. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.6.1. MRSA
    • 7.6.2. Clostridium Difficile
    • 7.6.3. Respiratory Virus
    • 7.6.4. TB and Drug-resistant TB
    • 7.6.5. Gonorrhea
    • 7.6.6. HPV
    • 7.6.7. HIV
    • 7.6.8. Hepatitis C
    • 7.6.9. Hepatitis B
    • 7.6.10. COVID-19
    • 7.6.11. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.7.1. Point-of-care
    • 7.7.2. Central Laboratories
    • 7.7.3. Others
  • 7.8. Market Attractiveness Analysis

8. East Asia Infectious Disease In-vitro Diagnostics Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product Type
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 8.4.1. Instruments
    • 8.4.2. Reagents
    • 8.4.3. Software and Services
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 8.5.1. Immunoassay
    • 8.5.2. Molecular Diagnostics
    • 8.5.3. Microbiology
    • 8.5.4. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.6.1. MRSA
    • 8.6.2. Clostridium Difficile
    • 8.6.3. Respiratory Virus
    • 8.6.4. TB and Drug-resistant TB
    • 8.6.5. Gonorrhea
    • 8.6.6. HPV
    • 8.6.7. HIV
    • 8.6.8. Hepatitis C
    • 8.6.9. Hepatitis B
    • 8.6.10. COVID-19
    • 8.6.11. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.7.1. Point-of-care
    • 8.7.2. Central Laboratories
    • 8.7.3. Others
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Infectious Disease In-vitro Diagnostics Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product Type
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 9.4.1. Instruments
    • 9.4.2. Reagents
    • 9.4.3. Software and Services
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 9.5.1. Immunoassay
    • 9.5.2. Molecular Diagnostics
    • 9.5.3. Microbiology
    • 9.5.4. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.6.1. MRSA
    • 9.6.2. Clostridium Difficile
    • 9.6.3. Respiratory Virus
    • 9.6.4. TB and Drug-resistant TB
    • 9.6.5. Gonorrhea
    • 9.6.6. HPV
    • 9.6.7. HIV
    • 9.6.8. Hepatitis C
    • 9.6.9. Hepatitis B
    • 9.6.10. COVID-19
    • 9.6.11. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.7.1. Point-of-care
    • 9.7.2. Central Laboratories
    • 9.7.3. Others
  • 9.8. Market Attractiveness Analysis

10. Latin America Infectious Disease In-vitro Diagnostics Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 10.4.1. Instruments
    • 10.4.2. Reagents
    • 10.4.3. Software and Services
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 10.5.1. Immunoassay
    • 10.5.2. Molecular Diagnostics
    • 10.5.3. Microbiology
    • 10.5.4. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.6.1. MRSA
    • 10.6.2. Clostridium Difficile
    • 10.6.3. Respiratory Virus
    • 10.6.4. TB and Drug-resistant TB
    • 10.6.5. Gonorrhea
    • 10.6.6. HPV
    • 10.6.7. HIV
    • 10.6.8. Hepatitis C
    • 10.6.9. Hepatitis B
    • 10.6.10. COVID-19
    • 10.6.11. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.7.1. Point-of-care
    • 10.7.2. Central Laboratories
    • 10.7.3. Others
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Infectious Disease In-vitro Diagnostics Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product Type
    • 11.2.3. By Technology
    • 11.2.4. By Application
    • 11.2.5. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 11.4.1. Instruments
    • 11.4.2. Reagents
    • 11.4.3. Software and Services
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 11.5.1. Immunoassay
    • 11.5.2. Molecular Diagnostics
    • 11.5.3. Microbiology
    • 11.5.4. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.6.1. MRSA
    • 11.6.2. Clostridium Difficile
    • 11.6.3. Respiratory Virus
    • 11.6.4. TB and Drug-resistant TB
    • 11.6.5. Gonorrhea
    • 11.6.6. HPV
    • 11.6.7. HIV
    • 11.6.8. Hepatitis C
    • 11.6.9. Hepatitis B
    • 11.6.10. COVID-19
    • 11.6.11. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.7.1. Point-of-care
    • 11.7.2. Central Laboratories
    • 11.7.3. Others
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Becton, Dickinson and Company
    • 12.3.3. bioMerieux SA
    • 12.3.4. F. Hoffmann-La Roche, Ltd.
    • 12.3.5. Hologic, Inc. (Gen Probe)
    • 12.3.6. Abbott
    • 12.3.7. Quidel Corporation
    • 12.3.8. Siemens Healthineers AG
    • 12.3.9. Bio-Rad Laboratories, Inc.
    • 12.3.10. Danaher
    • 12.3.11. OraSure Technologies, Inc.
    • 12.3.12. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations